Loading…
Chinese genomics company providing DNA sequencing services and equipment, including prenatal genetic testing.
Chinese genomics company providing DNA sequencing services and equipment, including prenatal genetic testing.
Earns by running genetic tests in its own labs and billing hospitals, health programs and research buyers per test, with prenatal screening the volume line. It belongs to the BGI group, whose sequencing-machine maker is a separate listed company, so this arm sells results rather than instruments.
In one line: A Chinese Illumina/Natera hybrid.
Moat: narrow (scale, brand, installed base). Large sequencing scale and an early, dominant position in China's NIPT market.
Headquarters: Shenzhen, China · Employees: 3,580
Size BGI Genomics (300676.SZ) is a China Health Care company (Biotechnology) with a market value of $2.39B, the 1079th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥38.39 on 6 Nov 2026.
Performance Over six months the shares fell 3.9%, against +8.1% for the median peer and -16.4% for the China market (cap-weighted) — 9th lowest of 20 in its peer set.
Growth Revenue grew 0.3% over the last twelve months (peer median +0.2%); the operating margin is -13.6% (peer median -25.4%).
Valuation It trades at 142.2× forward earnings against a peer median of 28.6× (most expensive of 5).
Capital Return on invested capital runs 11.0 points below its cost of capital (9.7% WACC).
Next results Next results expected around 26 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥3.72B | CN¥3.70B | CN¥3.86B | CN¥4.34B | CN¥7.05B |
| Revenue growth | — | -4% | -11% | -38% | — |
| Gross profit | CN¥1.60B | CN¥1.20B | CN¥1.41B | CN¥2.02B | CN¥3.55B |
| EBITDA | n/a | CN¥5.14M | -CN¥132M | CN¥583M | CN¥1.22B |
| Net income | -CN¥545M | -CN¥617M | -CN¥903M | CN¥92.9M | CN¥803M |
| Free cash flow | -CN¥223M | -CN¥496M | -CN¥336M | -CN¥587M | -CN¥1.03B |
| Capital expenditure | CN¥550M | CN¥506M | CN¥529M | CN¥1.24B | CN¥1.27B |
| Total debt | CN¥785M | CN¥784M | CN¥686M | CN¥1.23B | CN¥1.25B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| BGI Genomics 300676.SZ | $2.39B | -4% | 0% | -14% | 142.2× | n/a |
| Illumina ILMN | $32.2B | +50% | +6% | 21% | 35.7× | 27.1% |
| Natera NTRA | $44.8B | +60% | +38% | -11% | n/a | n/a |
| Berry Genomics 000710.SZ | $504M | -5% | -2% | -24% | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300676.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -12.3% | +0.6% | 4th lowest of 21 |
| 6-month return | -3.9% | +8.1% | 9th lowest of 20 |
| Distance from 52-week high | -40.9% | -31.1% | 7th lowest of 21 |
| Revenue growth (TTM) | +0.3% | +0.2% | 8th highest of 16 |
| Operating margin | -13.6% | -25.4% | 6th highest of 14 |
| Forward P/E | 142.2× | 28.6× | most expensive of 5 |
| ROIC minus cost of capital | -11.0 pp | -12.1 pp | 6th highest of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| BGI Genomics 300676.SZ | China | $2.39B | -4% | 0% | -14% | 142.2× | n/a | n/a |
| Pharvaris PHVS | United States | $2.41B | +14% | n/a | n/a | n/a | n/a | n/a |
| Celldex Therapeutics CLDX | United States | $2.35B | -12% | -97% | -206,220% | n/a | n/a | n/a |
| Zealand Pharma A/S ZEAL.CO | Denmark | $2.32B | -32% | -49% | 51% | 8.8× | n/a | n/a |
| MBX Biosciences MBX | United States | $2.47B | +25% | n/a | n/a | n/a | n/a | n/a |
| Hemab Therapeutics COAG | United States | $2.29B | +95% | n/a | n/a | n/a | n/a | n/a |
| Septerna SEPN | United States | $2.28B | +105% | +13,520% | -57% | n/a | 18.7% | n/a |
| Vimian VIMIAN.ST | Sweden | $2.26B | +41% | +8% | 19% | 37.5× | 12.5% | +44.5% |
| Sinocelltech 688520.SS | China | $2.25B | -23% | -40% | -75% | n/a | n/a | n/a |
| Palvella Therapeutics PVLA | United States | $2.53B | +45% | -100% | n/a | n/a | n/a | n/a |
| SKBS 302440.KS | South Korea | $2.22B | -11% | +23% | -25% | n/a | n/a | n/a |
| Immunome IMNM | United States | $2.21B | -17% | -100% | n/a | n/a | n/a | n/a |
| Evopoint Biosciences 688837.SS | China | $2.58B | n/a | n/a | n/a | n/a | n/a | n/a |
| Aurinia Pharmaceuticals AUPH | United States | $2.21B | +8% | +21% | 45% | 19.7× | 5.1% | +41.4% |
| Arcus Biosciences RCUS | United States | $2.59B | -28% | -55% | -415% | n/a | n/a | n/a |
| Recursion Pharmaceuticals RXRX | United States | $2.19B | +6% | +56% | -725% | n/a | n/a | n/a |
| Lakefront Biotherapeutics LKFT.AS | Netherlands | $2.19B | +25% | +259% | 60% | n/a | n/a | n/a |
| Vera Therapeutics VERA | United States | $2.15B | -18% | n/a | n/a | n/a | n/a | n/a |
| Xencor XNCR | United States | $2.66B | +178% | -29% | -206% | n/a | n/a | n/a |
| Hebei Changshan Biochemical Pharmaceutical 300255.SZ | China | $2.68B | -52% | 0% | -25% | n/a | n/a | n/a |
| Hitgen 688222.SS | China | $2.12B | +23% | +42% | 27% | 94.1× | 38.7% | +16.8% |